Long COVID Statistics in US 2026 | Patients, Symptoms, Impact & Facts

What is Long COVID?

Long COVID — also known as Post-COVID Conditions (PCC) or Post-Acute Sequelae of SARS-CoV-2 infection (PASC) — is defined by the CDC as new, returning, or ongoing health problems that occur four or more weeks after first being infected with SARS-CoV-2, the virus that causes COVID-19. It is not a single disease but a complex, multisystem syndrome encompassing more than 200 documented symptoms spanning neurological, cardiovascular, pulmonary, gastrointestinal, and immune pathways. The National Academies of Sciences, Engineering, and Medicine formally characterized Long COVID in 2024 as “a chronic, systemic disease state with profound consequences” — a landmark classification that affirmed the condition’s legitimacy as a distinct, serious medical entity, not a psychological artifact or a vague post-illness complaint. Symptoms can last for weeks, months, or years after acute infection, and critically, they can occur even in people who had mild or asymptomatic initial illness. The CDC’s surveillance and clinical guidance, updated as recently as May 6, 2026, continues to classify Long COVID as a major public health concern requiring dedicated clinical pathways, workforce preparation, and population-level monitoring.

Understanding the Long COVID statistics in the US in 2026 requires navigating a genuinely complex data landscape. Multiple federal surveillance systems — the National Health Interview Survey (NHIS), the Household Pulse Survey (HPS), the Behavioral Risk Factor Surveillance System (BRFSS), and the NIH-funded RECOVER initiative — each produce prevalence estimates that differ meaningfully depending on their study design, case definition, and the populations sampled. Estimates of adults who have ever experienced Long COVID range from approximately 6.4% to 18% across these systems, reflecting genuine methodological differences rather than measurement error. What they all agree on is the scale: millions of Americans are affected, hundreds of thousands are significantly disabled, the economic and workforce costs are measured in the hundreds of billions of dollars annually, and the healthcare system has been slow to build the clinical capacity to respond. The data in this article is sourced exclusively from peer-reviewed federal publications, CDC surveillance reports, MMWR analyses, NIH-funded research, and verified government-linked economic analyses.

Key Facts: Long COVID Statistics in the US 2026

The following table captures the most essential and well-documented Long COVID facts 2026 — all drawn from verified federal surveillance systems, government-funded research, or peer-reviewed publications in federal health journals.

Data Sources: CDC — Tracking Long COVID Dashboard (updated March 9, 2026); CDC MMWR Vol. 73/No. 50 — “Notes from the Field: Long COVID…by Jurisdiction — United States, 2023” (December 19, 2024); Vahratian A et al. JAMA Network Open 2024;7(12):e2451151; Ford ND et al. JAMA Pediatrics 2025;179(4):471–473; NIH RECOVER Initiative — “2024 Update of the RECOVER-Adult Long COVID Research Index” (JAMA, 2024); Brookings Metro — “New data shows Long COVID is keeping as many as 4 million people out of work” (2022); CDC — Preventing Chronic Disease, Pike J et al. (2023)

These 24 statistics, taken together, document a condition that by any public health measure qualifies as a mass disability event — one that the US healthcare and economic systems are still processing years after the acute phase of the pandemic ended. The 6.4% current prevalence among US adults, drawn from the CDC’s 2023 BRFSS data and published in the MMWR in December 2024, translates to roughly 16 million adults actively experiencing Long COVID symptoms at any given point — a number that exceeds the US prevalence of many better-known chronic conditions, including rheumatoid arthritis and multiple sclerosis. The 19.8% of those Long COVID patients who report significant activity limitation — meaning their symptoms reduce their ability to carry out day-to-day activities “a lot” — represents approximately 3.2 million Americans whose functional capacity is severely impaired by the condition. The economic consequences of that impairment, compounded over years of lost productivity and elevated healthcare utilization, are what drive the Brookings and Harvard estimates of $168–$230 billion in annual lost earnings and $9,000 per patient per year in direct medical costs.

Long COVID Prevalence Trends in the US 2026

Long COVID Prevalence Among US Adults — Trend Over Time
(CDC Household Pulse Survey & BRFSS; all adults regardless of prior COVID-19 history)

Jun 2022  |███████████████████████████████████  7.5% ← Peak (HPS)
Sep 2022  |█████████████████████████████████    7.2%
Jan 2023  |███████████████████████████          6.0% (HPS — stabilized)
mid-2023  |██████████████████████████           6.4% (BRFSS — current)
2022 NHIS |██████████████████████████████       6.9% (ever had Long COVID)
RECOVER   |██████████████████████████████████████████ ~18% (ever, prior-infected adults)
           ─────────────────────────────────────────────────────────────────
           0%       5%      7.5%     10%       15%       18%       20%
           ↑                  ↑                   ↑
       Children (1.4%)  National avg (6.4%)  RECOVER estimate

Data Sources: CDC — Tracking Long COVID (updated March 9, 2026); Ford ND et al. CDC MMWR 2023;72(32):859–65; Ford ND et al. MMWR Morb Mortal Wkly Rep 2024;73:1142–1143; Vahratian A et al. JAMA Network Open 2024;7(12):e2451151; Ford ND et al. JAMA Pediatrics 2025;179(4):471–473; NIH RECOVER — 2024 Update RECOVER-Adult Long COVID Research Index (JAMA 2024); AHRQ MEPS Statistical Brief #557 (2024)

The Long COVID prevalence trend in the US from 2022 to 2026 follows a pattern that any serious public health response must grapple with honestly: an initial peak, a partial decline as acute Omicron-wave infections resolved, and then a stabilization plateau from which prevalence has not meaningfully declined further. The CDC Household Pulse Survey data — the highest-frequency surveillance tool — showed Long COVID dropping from a peak of 7.5% of all US adults in June 2022 to 6.0% in June 2023, before stabilizing. The 2023 BRFSS data, published in the MMWR in December 2024, found the same 6.4% figure for current Long COVID — confirming that the condition’s prevalence has become structurally embedded in the population rather than continuing to dissipate. The apparent discrepancy between the 6–7% NHIS/BRFSS estimates and the NIH RECOVER figure of ~20% likely Long COVID among prior-infected adults is methodological, not contradictory: BRFSS and NHIS survey the general population regardless of prior COVID-19 history, while RECOVER follows a cohort of people who had documented SARS-CoV-2 infection and systematically screens for Long COVID symptoms. Both numbers are accurate for their respective denominators and both are alarming.

The children’s data from the 2025 JAMA Pediatrics publication — drawing on 2023 NHIS responses — shows pediatric Long COVID prevalence at 1.4% ever and 0.4% currently, with the highest rates among adolescents aged 12–17 at 2.3%, a pattern consistent with the RECOVER-Pediatrics cohort, which found approximately 20% of school-age children and 14% of teenagers with prior COVID-19 infection likely met Long COVID criteria. The 80% activity limitation rate among children with Long COVID reported in the JAMA Pediatrics 2025 paper is one of the most striking pediatric statistics in this dataset — it suggests that among the children who do experience persistent post-COVID symptoms, the functional impact on school attendance, daily activities, and quality of life is nearly universal, not a minority phenomenon.

Long COVID Symptoms in the US 2026

Top Long COVID Symptoms — NIH RECOVER-Adult Updated Index (JAMA 2024)
(Most differentiating symptoms between prior-infected and non-infected participants; n=13,647)

Post-Exertional Malaise (PEM)   |████████████████████████████████████████  Most differentiating
Fatigue                         |███████████████████████████████████████▌
Brain Fog                       |███████████████████████████████████████
Dizziness                       |████████████████████████████████████▌
Palpitations                    |████████████████████████████████████
Change in smell or taste        |███████████████████████████████████▌
Chronic cough                   |██████████████████████████████████
Chest pain                      |█████████████████████████████████▊
Shortness of breath             |█████████████████████████████████▌
Sleep apnea                     |█████████████████████████████████
Thirst (new/changed)            |████████████████████████████████
                                 ──────────────────────────────────────────────────
                                 Source: 2024 RECOVER-Adult Long COVID Research Index, JAMA 2024
                                 Score ≥11 = highly symptomatic Long COVID

Data Sources: NIH RECOVER Initiative — “2024 Update of the RECOVER-Adult Long COVID Research Index,” JAMA 2024 (13,647 participants, 83 US sites); CDC — Long COVID Signs and Symptoms (updated March 10, 2026); NIH RECOVER — “New Insights on Long COVID Symptoms in Adults” (recovercovid.org, December 2024)

The 2024 NIH RECOVER Long COVID symptom index — the most rigorously constructed federal classification tool for Long COVID to date — identified 11 core discriminating symptoms that most clearly separate people with prior SARS-CoV-2 infection from those without, using data from 13,647 participants across 83 US sites and Puerto Rico. The expansion from the 2023 original index (which analyzed 44 symptoms in 9,764 participants) to the 2024 update (52 symptoms in 13,647 participants) reflects both the growing clinical evidence base and the direct input of patient and community feedback, which specifically identified sleep apnea and unusual thirst as symptoms not captured in the original model. The index classifies Long COVID into five distinct subtypes based on symptom clustering — a crucial methodological advance because it confirms that “Long COVID” is not a single phenotype but a family of related conditions that may have different underlying mechanisms and require different clinical management approaches.

Post-Exertional Malaise (PEM) — the worsening of symptoms following physical or mental activity, often delayed by 12–72 hours — consistently emerges as the most clinically significant and functionally disabling symptom in this dataset. PEM is also the hallmark feature of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a condition that has long been recognized as potentially triggered by viral infections, and research published in 2024 found that a substantial proportion of Long COVID patients meet diagnostic criteria for ME/CFS, suggesting shared pathophysiological mechanisms. The brain fog cluster — encompassing difficulty concentrating, memory impairment, and cognitive slowdown — is particularly significant because it directly impairs patients’ ability to work, attend school, and maintain social relationships, making it a primary driver of the Long COVID-associated disability and workforce exit documented in the economic impact data. The CDC’s current clinical guidance, updated in 2026, explicitly notes that no laboratory test can definitively diagnose Long COVID — it remains a clinical diagnosis based on symptom history and the exclusion of other causes.

Long COVID Demographics and Risk Factors in the US 2026

Long COVID Risk by Demographics — US (2022 NHIS & BRFSS; CDC NCHS Data Brief 480)

By Age Group (ever had Long COVID):
Ages 35–49   |████████████████████████  8.9% — highest of all age groups
Ages 50–64   |████████████████████████  7.6%
Ages 18–34   |█████████████████████     6.9%
Ages 65+     |██████████████            4.1% — lowest (survival bias + immunity)

By Sex:
Women        |████████████████████████████  Higher risk (consistent across surveys)
Men          |████████████████████          Lower risk in all categories

By Poverty Level / Insurance:
Uninsured    |████████████████████████████████  17.7% ever had Long COVID (MEPS 2023)
Public only  |█████████████████████████████     17.2%
Private      |████████████████████              12.4%

Geographic pattern: Higher in South, Midwest, and West; lower in New England

Data Sources: CDC NCHS Data Brief No. 480 — “Long COVID in Adults: United States, 2022” (Adjaye-Gbewonyo D et al., NCHS, 2023); AHRQ Medical Expenditure Panel Survey (MEPS) Statistical Brief #557 — “Prevalence of Long COVID Among Adults Who Have Ever Had COVID-19” (Spring 2023, published 2024); NHIS/BRFSS multivariate analysis (medRxiv, 2024.01.12.24301170)

The demographics of Long COVID in the US in 2026 reveal a condition that does not strike evenly across the population — and the pattern of who is most affected carries significant implications for healthcare access, workforce policy, and social equity. The 35–49 age group’s 8.9% ever-prevalence stands out as the highest of any adult demographic, a finding that matters enormously because this age group represents the core of the US workforce — the cohort most likely to be in prime earning years, carrying mortgages, raising children, and serving in high-responsibility roles. When this age group exits the workforce or reduces hours due to Long COVID disability, the ripple effects on household finances, employer productivity, and the broader economy are disproportionately large. The lower prevalence in adults 65 and older (4.1% ever) is counterintuitive given their higher COVID-19 mortality risk, but reflects a combination of survivor bias (those who survived severe acute illness may not develop Long COVID), higher vaccination rates, and potential differences in how older adults perceive and report chronic symptoms.

The female risk elevation is one of the most consistently documented findings across all Long COVID surveillance systems in the US — NHIS, BRFSS, Household Pulse Survey, and RECOVER all find that women report Long COVID at substantially higher rates than men, a pattern that parallels other post-viral syndromes including ME/CFS. The insurance and income gradient is equally stark: uninsured adults report ever having Long COVID at a rate of 17.7% compared to 12.4% among the privately insured, a disparity that almost certainly reflects both greater COVID-19 exposure risk in lower-income occupations and reduced access to the clinical care that would facilitate Long COVID diagnosis and management. Severe acute COVID-19 is the strongest single predictor of Long COVID across all analyses — those who were hospitalized or had severe acute illness face dramatically elevated risk — but critically, mild and even asymptomatic acute infection does not protect against Long COVID, making prevention through vaccination and infection control the most robust available strategy.

Long COVID’s Economic and Workforce Impact in the US 2026

Economic Impact of Long COVID — US Estimates

Annual lost earnings (Brookings, 3–4M workers out):
  $168–$230 billion/year     |████████████████████████████████████████████████████████████████
  = ~1% of US GDP

Annual per-patient medical costs (Harvard/Cutler estimate):
  ~$9,000/patient/year       |██████████████████████████████████████

5-year cumulative excess medical cost per patient (EHR study):
  $7,124 excess vs. matched  |███████████████████████████

Direct medical costs vs. non-COVID patients at 6 months:
  Adults: 1.46× higher       |██████████████████████████████████████████████
  Children: 1.70× higher     |████████████████████████████████████████████████████

Global annual economic cost (Nature Medicine 2024):
  ~$1 trillion               |████████████████████████████████████████████████████████████████

Data Sources: Brookings Metro — “New Data Shows Long COVID Is Keeping as Many as 4 Million People Out of Work” (August 24, 2022); Brookings Papers on Economic Activity — Abraham & Rendell (2023); HHS ASPE — “Long COVID Among Essential Workers” (January 2025); CDC Preventing Chronic Disease — Pike J et al., “Direct Medical Costs Associated with Post-COVID-19 Conditions” (2023, doi:10.5888/pcd20.220292); npj Primary Care Respiratory Medicine — “Economic Burden of Long COVID: Macroeconomic, Cost-of-Illness and Microeconomic Impacts” (November 2025); Nature Medicine — Al-Aly Z et al. 2024

The economic impact of Long COVID in the US in 2026 is not a projection or a theoretical concern — it is a documented, ongoing drag on the workforce, on household finances, and on the healthcare system that is measurable across multiple independent methodologies. The Brookings Institution’s analysis, drawing on US Current Population Survey data and the average weekly US wage of $1,106, calculated that the 3–4 million Americans out of work due to Long COVID translates into $168–$230 billion in annual lost earnings — equivalent to approximately 1% of total US GDP. Harvard economist David Cutler, using a different methodology based on COVID-19 case counts, labor force participation rates, and the 70% labor force reduction observed in those with significant Long COVID impairment, arrived at a nearly identical figure of approximately $200 billion in annual lost wages, with a cumulative 5-year cost estimate of $1 trillion in lost earnings alone — before accounting for medical costs, caregiver burden, or reduced productivity among those remaining employed.

The direct medical cost data from CDC’s own Preventing Chronic Disease publication (Pike et al., 2023) established that Long COVID patients incur healthcare costs at 1.46× to 1.82× the rate of matched non-COVID controls across 1, 3, and 6-month windows after acute infection. A subsequent retrospective EHR study of 12 hospitals and 20 community health centers, covering data from January 2018 through December 2024, found that contrary to the assumption that post-acute healthcare costs would attenuate as patients recovered, Long COVID healthcare costs showed progressively widening trajectories over five years — driven primarily by increasing utilization rather than increased care intensity. The cumulative 5-year excess cost of $7,124 per Long COVID patient (mortality-adjusted) challenges the premise that Long COVID is a finite, self-resolving condition for most patients. Combined with the $9,000 average annual per-patient cost estimated by Harvard’s Cutler — with potentially half paid out-of-pocket — Long COVID represents one of the largest single sources of avoidable healthcare expenditure and financial hardship in the current US health system.

Long COVID Geographic and State-Level Statistics in the US 2026

Long COVID Prevalence — Selected US States & Jurisdictions, 2023
(CDC MMWR Vol. 73 No. 50, December 19, 2024 — 2023 BRFSS data; current Long COVID)

West Virginia     |████████████████████████████████████████  9.7% ← Highest state
Idaho             |████████████████████████████████████████  ≥8.0% (high quintile)
Puerto Rico       |████████████████████████████████████████  ≥8.0% (high quintile + highest activity limitation 29.4%)
Montana / Wyoming |████████████████████████████████████      8.9–10.6% range (2022 BRFSS)
National Average  |████████████████████████████              6.4%
DC                |███████████████████████                   Moderate — lowest activity limitation 12.8%
US Virgin Islands |████████                                  2.9% ← Lowest jurisdiction
                   ─────────────────────────────────────────────────────────────────
                   0%       2%        4%       6%       8%       9.7%    10%+

Data Sources: CDC MMWR Morb Mortal Wkly Rep 2024;73(50):1142–1143 — Ford ND, Agedew A et al. (December 19, 2024); CDC MMWR Morb Mortal Wkly Rep 2024;73(7) — Ford ND et al. (February 15, 2024), state-level BRFSS 2022 analysis; CIDRAP — “Long COVID incidence in US varies by state, highest in West Virginia” (February 15, 2024)

The geographic distribution of Long COVID in the US is not random, and the pattern that has emerged across successive CDC surveillance analyses carries clear implications for health equity and resource allocation. West Virginia’s 9.7% current Long COVID prevalence — the highest of any state in the 2023 MMWR analysis — is consistent with the state’s broader health burden profile: high rates of chronic disease, lower educational attainment, limited healthcare access in rural areas, and lower vaccination uptake. The Mountain West cluster of Montana, Wyoming, and North Dakota showing rates between 8.9% and 10.6% in 2022 BRFSS data similarly reflects a combination of rural healthcare access challenges, higher rates of prior COVID-19 infection in less vaccinated populations, and the occupational profile of the workforce in those states. Puerto Rico’s combination of high prevalence and the highest activity limitation rate (29.4%) across all jurisdictions studied is the most alarming single jurisdiction finding in the entire dataset — it means that in Puerto Rico, nearly 3 in 10 adults with Long COVID report that their symptoms reduce their daily functioning “a lot.”

The consistent finding that New England states fall below the national average in Long COVID prevalence while Southern, Mountain West, and Great Plains states exceed it mirrors the geographic patterns of COVID-19 vaccination uptake — the most consistent evidence-based risk reduction strategy for Long COVID. The CDC’s own public health guidance, updated through March 2026, explicitly recommends updated COVID-19 vaccination as the primary prevention tool for Long COVID, citing research showing that vaccination reduces Long COVID risk even when breakthrough infections occur. The jurisdiction-specific data from the MMWR — the most granular federal surveillance output on Long COVID state differences — is designed precisely to allow states and territories to calibrate their public health planning, Long COVID clinic capacity, and workforce support policies to their actual burden levels, rather than relying solely on national averages that obscure substantial geographic inequality.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE